Disease & disorder

AIDS

MONDO:0012268

A syndrome resulting from the acquired deficiency of cellular immunity caused by the human immunodeficiency virus (HIV). It is characterized by the reduction of the Helper T-lymphocytes in the peripheral blood and the lymph nodes. Symptoms include generalized lymphadenopathy, fever, weight loss, and chronic diarrhea. Patients with AIDS are especially susceptible to opportunistic infections (usually pneumocystis carinii pneumonia, cytomegalovirus (CMV) infections, tuberculosis, candida infections, and cryptococcosis), and the development of malignant neoplasms (usually non-Hodgkin lymphoma and Kaposi sarcoma). The human immunodeficiency virus is transmitted through sexual contact, sharing of contaminated needles, or transfusion of contaminated blood.

Clinical trials186
Recruiting11
Drug concepts studied20
Synonyms5

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.

Medications under investigation

Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.

Loading mapped interventions…

MONDO disease family

Loading verified ontology relationships…

Recruiting studies by city

Loading research-site locations…

Trial status

Loading…

Trial phase

Loading…

Study start year

Loading…

Investigated drug interventions

Loading…
Background context

HIV/AIDS

The human immunodeficiency virus (HIV) is a retrovirus that attacks the immune system. Without treatment, it can lead to a spectrum of conditions including acquired immunodeficiency syndrome (AIDS). It is a preventable disease. It can be managed with treatment and become a manageable chronic health condition. While there is no cure or vaccine for HIV, antiretroviral treatment can slow the course of the disease, and, if used before significant disease progression, can extend the life expectancy of someone living with HIV to a nearly standard level. An HIV-positive person on treatment can expect to live a normal life, and die with the virus, not of it. Effective treatment for HIV-positive people (people living with HIV) involves a life-long regimen of medicine to suppress the virus, making the viral load undetectable. Early testing can show if treatment is needed to stop progression and to prevent infecting others. Treatment is recommended as soon as the diagnosis is made. An HIV-positive person who has an undetectable viral load as a result of long-term treatment has effectively no risk of transmitting HIV sexually. Campaigns by UNAIDS and other organizations around the world have communicated this as Undetectable = Untransmittable. Without treatment the infection can interfere with the immune system, and eventually progress to AIDS, sometimes taking many years. Following initial infection an individual may not notice any symptoms, or may experience a brief period of influenza-like illness. During this period the person may not know that they are HIV-positive, yet they wi...

Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
Implementing Depression and Adherence TreatmentNCT07032363 · 2026-05-20
RECRUITING
BRAZILIAN REGISTRY OF CHRONIC NON-COMMUNICABLE DISEASES IN PEOPLE LIVING WITH HIV/AIDSNCT07118683 · 2025-08-15
RECRUITING
The Collaborative Care PrTNER StudyNCT06585631 · 2025-01-02
RECRUITING
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan AfricaNCT05373758 · 2024-02-07
RECRUITING
Mesenchymal Stem Cells Treatment for AIDS Patients at Late StageNCT05939167 · 2023-12-10
RECRUITING
Risk Identification Factors for Pulmonary Function Impairment in AIDS Patients Recovered From Severe PneumoniaNCT06137196 · 2023-11-01
RECRUITING
Metagenomic Next-Generation Sequencing Guides Anti-Infection StrategiesNCT06145841 · 2023-10-23
RECRUITING
Functional Cure of Hepatitis B in HIV/HBV Co-infected PatientsNCT05988879 · 2023-08-02
RECRUITING
Economic Navigation and Strengthening to Research Unrestricted Services for Transgender Women (ENTRUST)NCT06202898 · 2023-07-11
RECRUITING
Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood SpotNCT05390424 · 2022-12-02
RECRUITING
The DC Cohort Longitudinal HIV Status Neutral StudyNCT01206920 · 2011-01-01
RECRUITING
Disease Evolution and Risk Factors of AIDS-related Prevalent CancersNCT07696169 · 2026-07-01
NOT_YET_RECRUITING
Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDSNCT07579247 · 2026-05-01
NOT_YET_RECRUITING
Engaging Pharmacists to Advance Tobacco Treatment Service DeliveryNCT07501624 · 2026-02-11
ENROLLING_BY_INVITATION
The Quality of Life and Viral Control Effect of AIDS Patients After Long-acting Injection of Cabotegravir and RilpivirineNCT07131826 · 2025-08-15
NOT_YET_RECRUITING
ALHIV Smartphone Game StudyNCT06913660 · 2025-04-07
COMPLETED
HIV HOspital TEsting: Bringing the Hidden to Light in the Hospital SettingNCT06282328 · 2024-02-14
COMPLETED
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWHNCT06044792 · 2023-09-30
NOT_YET_RECRUITING
The Living With a Long-Term Condition StudyNCT06072287 · 2023-06-28
UNKNOWN
Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIVNCT06045923 · 2023-03-17
TERMINATED
The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS EventsNCT05421286 · 2022-09-28
ACTIVE_NOT_RECRUITING
Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV DiseaseNCT04808908 · 2021-04-01
COMPLETED
Community-Based Model for Delivery of Antiretroviral Therapy in CambodiaNCT04766710 · 2021-04-01
COMPLETED
COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDSNCT04754698 · 2021-02-09
COMPLETED
Standardized Patients to Measure and Address Intersectional StigmaNCT04896216 · 2020-11-24
COMPLETED
Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected WomenNCT03633721 · 2020-10-23
COMPLETED
Reducing Time to Spaced-out Appointments for Newly-diagnosed People Living With HIVNCT04567693 · 2020-10-22
COMPLETED
Antiretroviral Adherence and Drug-level MonitoringNCT05996094 · 2020-10-16
UNKNOWN
Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells LymphocytesNCT04770701 · 2020-09-20
WITHDRAWN
Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSMNCT03661203 · 2020-09-01
UNKNOWN
Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary CareNCT03670316 · 2020-08-17
COMPLETED
Intervention Program to Address PTSD in People Living With HIVNCT05588596 · 2020-05-03
COMPLETED
Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS PatientsNCT04059770 · 2020-02-14
COMPLETED
N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIVNCT04144335 · 2020-01-01
WITHDRAWN
Adolescent to Adult Patient-centered HIV Transition (ADAPT) StudyNCT02872805 · 2019-11-01
COMPLETED
Treatment of PD-1 Inhibitor in AIDS-associated PMLNCT04091932 · 2019-08-20
UNKNOWN
Effect on HIV Medications on EPC CellsNCT03782142 · 2018-11-01
COMPLETED
Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With TuberculosisNCT03478033 · 2018-04-15
UNKNOWN
An Efficacy and Safety Study of shRNA-modified CD34+ Cells in HIV-infected Patients.NCT03517631 · 2018-02-27
UNKNOWN
A Drug Safety and Dose-exploratory Clinical Study of Azvudine Tablets in Patients Who Have Not Received Anti-HIV TreatmentNCT04109183 · 2017-10-10
COMPLETED

Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.